Literature DB >> 12922167

Mapping of regions within the vaccinia virus complement control protein involved in dose-dependent binding to key complement components and heparin using surface plasmon resonance.

Scott A Smith1, R Sreenivasan, Gunasekaran Krishnasamy, Ken W Judge, Krishna H Murthy, Shrihari J Arjunwadkar, David R Pugh, Girish J Kotwal.   

Abstract

The vaccinia virus complement control protein (VCP) is involved in modulating the host inflammatory response by blocking both pathways of complement activity through its ability to bind C3b and C4b. Other activities arise from VCP's ability to strongly bind heparin. To map regions within VCP involved in binding complement and heparin experimentally, surface plasmon resonance (SPR) and recombinantly expressed VCP (rVCP) constructs were employed. Using C3b or heparin as the immobilized ligand, various rVCP constructs were tested for their ability to bind. Results suggest that VCP is the smallest functional unit able to bind C3b, thereby blocking complement activity, and only a single site, the large basic region near the C-terminus, is involved in heparin binding. Kinetic analysis was also performed to determine the relative binding affinities between rVCP and complement (C3-MA and C4b), as well as rVCP and heparin. rVCP was found to possess a significantly greater affinity for C3-MA than C4b, as indicated by the 1.50e3-fold greater association rate constant (k(a)). This study provides insights for the design of new therapeutic proteins capable of blocking complement activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922167     DOI: 10.1016/s1570-9639(03)00189-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Identification of complement regulatory domains in vaccinia virus complement control protein.

Authors:  Jayati Mullick; John Bernet; Yogesh Panse; Sharanabasava Hallihosur; Akhilesh K Singh; Arvind Sahu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  Ectromelia virus inhibitor of complement enzymes protects intracellular mature virus and infected cells from mouse complement.

Authors:  Elizabeth A Moulton; Paula Bertram; Nanhai Chen; R Mark L Buller; John P Atkinson
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins.

Authors:  Georgia Sfyroera; Madan Katragadda; Dimitrios Morikis; Stuart N Isaacs; John D Lambris
Journal:  J Immunol       Date:  2005-02-15       Impact factor: 5.422

4.  Disabling complement regulatory activities of vaccinia virus complement control protein reduces vaccinia virus pathogenicity.

Authors:  John Bernet; Muzammil Ahmad; Jayati Mullick; Yogesh Panse; Akhilesh K Singh; Pradeep B Parab; Arvind Sahu
Journal:  Vaccine       Date:  2011-07-29       Impact factor: 4.169

5.  Investigation of interaction of vaccinia virus complement control protein and curcumin with complement components c3 and c3b using quartz crystal microbalance with dissipation monitoring technology.

Authors:  Amod P Kulkarni; Philippa J Randall; Krishna Murthy; Lauriston A Kellaway; Girish J Kotwal
Journal:  Open Biochem J       Date:  2010-01-27

6.  Structure of vaccinia complement protein in complex with heparin and potential implications for complement regulation.

Authors:  Vannakambadi K Ganesh; Scott A Smith; Girish J Kotwal; Krishna H M Murthy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-03       Impact factor: 11.205

Review 7.  Monkeypox virus and insights into its immunomodulatory proteins.

Authors:  Jessica R Weaver; Stuart N Isaacs
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

8.  Kinetic analysis of the interactions between vaccinia virus complement control protein and human complement proteins C3b and C4b.

Authors:  John Bernet; Jayati Mullick; Yogesh Panse; Pradeep B Parab; Arvind Sahu
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  C4b Binding Protein Acts as an Innate Immune Effector Against Influenza A Virus.

Authors:  Praveen M Varghese; Valarmathy Murugaiah; Nazar Beirag; Nigel Temperton; Haseeb A Khan; Salman H Alrokayan; Mohammed N Al-Ahdal; Beatrice Nal; Futwan A Al-Mohanna; Robert B Sim; Uday Kishore
Journal:  Front Immunol       Date:  2021-01-08       Impact factor: 7.561

10.  Interaction of triosephosphate isomerase from the cell surface of Staphylococcus aureus and alpha-(1->3)-mannooligosaccharides derived from glucuronoxylomannan of Cryptococcus neoformans.

Authors:  Hiromi Furuya; Reiko Ikeda
Journal:  Microbiology (Reading)       Date:  2009-05-07       Impact factor: 2.777

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.